Mon, Jul

A combination of 2 antibody drugs shrank tumors in 40% of women with breast cancer whose tumors generate HER2 - Reuters (article link)

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

- T-DM1 -- an "armed antibody" that ties Roche Herceptin to a toxic chemotherapy compound from ImmunoGen.
- results shrank tumors in 9 of 23 women whose cancer had worsened after a median of 8 prior treatments.
- Herceptin is designed to block the function of HER2, a protein produced by a specific gene with cancer-causing potential, 25-30% of breast cancers.

Antibody combo shrinks breast cancer tumors-study